Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer

Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer

To date, no research evaluating the predictive capabilities of soluble programmed cell death-ligand 1 (sPD-L1) in thyroid cancer patients has been performed. We aimed to investigate the prognostic significance of sPD-L1 expression in papillary thyroid cancer (PTC) and to evaluate the association bet...

Full description

Bibliographic Details
Main Authors:	Marra Jai Aghajani, Tara Laurine Roberts, Tao Yang, Charles Eugenio McCafferty, Nicole J Caixeiro, Paul DeSouza, Navin Niles
Format:	Article
Language:	English
Published:	Bioscientifica 2019-07-01
Series:	Endocrine Connections
Subjects:	thyroid cancer prognostic significance soluble programmed cell death-ligand 1 sPD-L1 survival
Online Access:	https://ec.bioscientifica.com/view/journals/ec/8/7/EC-19-0210.xml

Similar Items

Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma
by: Christopher Montemagno, et al.
Published: (2020-01-01)

The potential of soluble programmed death-ligand 1 (sPD-L1) as a diagnosis marker for colorectal cancer
by: Weifang Shao, et al.
Published: (2022-08-01)

Assessing the Clinical Relevance of Soluble PD-1 and PD-L1: A Multi-Cohort Study Across Diverse Tumor Types and Prognostic Implications
by: Nikolay E. Kushlinskii, et al.
Published: (2025-02-01)

High intensity interval exercise increases the frequency of peripheral PD-1+ CD8+ central memory T-cells and soluble PD-L1 in humans
by: Alex J. Wadley, et al.
Published: (2020-03-01)

Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer
by: Paul Buderath, et al.
Published: (2019-10-01)

The Prognostic Value of Serum Soluble Programmed Death 1 (sPD‐1) and Programmed Death Ligand 1 (sPD‐L1) in Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta‐Analysis About Cohort Studies
by: Qiyao Yu, et al.
Published: (2024-11-01)

Increased serum soluble PD-l1 levels in patients with advanced stages of chronic kidney disease
by: Ayaka Hayashi, et al.
Published: (2025-01-01)

Prognostic and predictive role of soluble programmed death ligand-1 in head and neck cancer
by: Maria Molga-Magusiak, et al.
Published: (2023-05-01)

Epstein–Barr Virus LMP1 Induces Soluble PD-L1 in Nasopharyngeal Carcinoma
by: Kina Kase, et al.
Published: (2021-03-01)

High Pretreatment Serum PD-L1 Levels Are Associated with Muscle Invasion and Shorter Survival in Upper Tract Urothelial Carcinoma
by: Ádám Széles, et al.
Published: (2022-10-01)

Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC
by: Ling Yi, et al.
Published: (2023-03-01)

Soluble programmed death molecule 1 (sPD-1) as a predictor of interstitial lung disease in rheumatoid arthritis
by: Li Xu, et al.
Published: (2021-10-01)

Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1
by: Karolina Okła, et al.
Published: (2020-06-01)

Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer
by: Yinjun He, et al.
Published: (2023-01-01)

Soluble immune checkpoint molecules: mechanism of formation, function, role in malignant neoplasms
by: T. V. Glazanova, et al.
Published: (2025-01-01)

Soluble forms of immune checkpoint receptor PD-1 and its ligand PD-L1 in plasma of patients with ovarian neoplasms
by: E. S. Gershtein, et al.
Published: (2018-12-01)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
by: Mengke Niu, et al.
Published: (2022-03-01)

The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study
by: Takashi Kurosaki, et al.
Published: (2023-12-01)

The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1+ regulator B cells mediates immunosuppression in triple-negative breast cancer
by: Xuejiao Li, et al.
Published: (2022-07-01)

It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer
by: Ingrid Garajová, et al.
Published: (2022-06-01)

The Potential Role of sPD-L1 as a Predictive Biomarker in EGFR-Positive Non-Small-Cell Lung Cancer
by: Vesna Ćeriman Krstić, et al.
Published: (2025-01-01)

Developing a risk score using liquid biopsy biomarkers for selecting Immunotherapy responders and stratifying disease progression risk in metastatic melanoma patients
by: Amalia Azzariti, et al.
Published: (2025-02-01)

Prognostic value of soluble programmed death-1 and soluble programmed death ligand-1 in severe traumatic brain injury patients
by: Lei Liu, et al.
Published: (2024-10-01)

Neoadjuvant Chemoradiotherapy Changes the Landscape of Soluble Immune Checkpoint Molecules in Patients With Locally Advanced Rectal Cancer
by: Chao Liu, et al.
Published: (2022-04-01)

Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy
by: Sinne Søberg Brun, et al.
Published: (2024-04-01)

A digital microfluidic device integrated with electrochemical sensor and 3D matrix for detecting soluble PD-L1
by: Yuqian Zhang, et al.
Published: (2024-08-01)

sPD-1/sPD-L1 proteins in non-small cell lung cancer and esophageal squamous cell carcinoma
by: I. S. Stilidi, et al.
Published: (2022-10-01)

Prognostic significance of soluble PD-L1 in prostate cancer
by: Margarita Zvirble, et al.
Published: (2024-07-01)

ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance
by: Jacob J. Orme, et al.
Published: (2020-01-01)

Soluble SPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer
by: Jovanović Dragana, et al.
Published: (2019-01-01)

Soluble programmed death-1 (sPD-1) and programmed death ligand 1 (sPD-L1) as potential biomarkers for the diagnosis and prognosis of glioma patients
by: Liu Shujun, et al.
Published: (2020-01-01)

Study on the efficacy of IFN-γ- and sPD-1-overexpressing BMSCs in enhancing immune effects for the treatment of lung adenocarcinoma
by: Yahui Xie, et al.
Published: (2025-03-01)

Soluble Levels of CD163, PD-L1, and IL-10 in Renal Cell Carcinoma Patients
by: Sabina Davidsson, et al.
Published: (2022-01-01)

Genetic Co-Administration of Soluble PD-1 Ectodomains Modifies Immune Responses against Influenza A Virus Induced by DNA Vaccination
by: Pierre Tannig, et al.
Published: (2020-10-01)

Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer
by: Stephan Kruger, et al.
Published: (2017-05-01)

The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
by: Xin-wei Qiao, et al.
Published: (2020-09-01)

Analysis of the mechanisms regulating soluble PD-1 production and function in human NK cells
by: Francesca Romana Mariotti, et al.
Published: (2023-08-01)

Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma
by: Inju Cho, et al.
Published: (2020-02-01)

Clinical Relevance of Soluble Forms of Immune Checkpoint Molecules sPD-1, sPD-L1, and sCTLA-4 in the Diagnosis and Prognosis of Ovarian Cancer
by: Janina Świderska, et al.
Published: (2022-01-01)

Peptide Blockers of PD-1-PD-L1 Interaction Reinvigorate PD-1-Suppressed T Cells and Curb Tumor Growth in Mice
by: Shanshan (Jenny) Zhong, et al.
Published: (2024-07-01)